MX2022014070A - Composiciones y metodos de arn circular. - Google Patents
Composiciones y metodos de arn circular.Info
- Publication number
- MX2022014070A MX2022014070A MX2022014070A MX2022014070A MX2022014070A MX 2022014070 A MX2022014070 A MX 2022014070A MX 2022014070 A MX2022014070 A MX 2022014070A MX 2022014070 A MX2022014070 A MX 2022014070A MX 2022014070 A MX2022014070 A MX 2022014070A
- Authority
- MX
- Mexico
- Prior art keywords
- circular
- rnas
- expression
- compositions
- circular rnas
- Prior art date
Links
- 108091028075 Circular RNA Proteins 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 2
- 239000002243 precursor Substances 0.000 abstract 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 abstract 1
- 108091027874 Group I catalytic intron Proteins 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 125000006850 spacer group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4214—Receptors for cytokines
- A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063022248P | 2020-05-08 | 2020-05-08 | |
| US202063087582P | 2020-10-05 | 2020-10-05 | |
| PCT/US2020/063494 WO2021113777A2 (en) | 2019-12-04 | 2020-12-04 | Circular rna compositions and methods |
| PCT/US2021/031629 WO2021226597A2 (en) | 2020-05-08 | 2021-05-10 | Circular rna compositions and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022014070A true MX2022014070A (es) | 2023-04-11 |
Family
ID=78468564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022014070A MX2022014070A (es) | 2020-05-08 | 2021-05-10 | Composiciones y metodos de arn circular. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230226096A1 (https=) |
| EP (1) | EP4146285A2 (https=) |
| JP (1) | JP2023525270A (https=) |
| CN (1) | CN116113419A (https=) |
| AU (1) | AU2021269137A1 (https=) |
| CA (1) | CA3178111A1 (https=) |
| MX (1) | MX2022014070A (https=) |
| WO (1) | WO2021226597A2 (https=) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3100276A1 (en) | 2018-06-06 | 2019-12-12 | Massachusetts Institute Of Technology | Circular rna for translation in eukaryotic cells |
| MX2023007137A (es) * | 2020-12-21 | 2023-08-28 | Beam Therapeutics Inc | Nanomateriales que comprenden acetales unidos a ésteres. |
| CN115997018A (zh) | 2021-03-10 | 2023-04-21 | 尔知渃米斯股份有限公司 | 自身环化rna构建体 |
| CA3211623A1 (en) | 2021-05-24 | 2022-12-01 | Bo YING | Lipid compounds and lipid nanoparticle compositions |
| CN113264842B (zh) * | 2021-07-21 | 2022-03-01 | 苏州科锐迈德生物医药科技有限公司 | 一种脂质化合物及包含其的脂质载体、核酸脂质纳米粒组合物和药物制剂 |
| TW202328067A (zh) | 2021-09-14 | 2023-07-16 | 美商雷納嘉德醫療管理公司 | 環狀脂質及其使用方法 |
| CN118317944A (zh) | 2021-09-14 | 2024-07-09 | 雷纳嘉德医疗管理公司 | 非环状脂质及其使用方法 |
| MX2024006440A (es) | 2021-11-24 | 2024-08-19 | Flagship Pioneering Innovations Vi Llc | Composiciones inmunogenicas y sus usos. |
| EP4436984A1 (en) | 2021-11-24 | 2024-10-02 | Flagship Pioneering Innovations VI, LLC | Coronavirus immunogen compositions and their uses |
| AU2022397292A1 (en) | 2021-11-24 | 2024-05-30 | Flagship Pioneering Innovations Vi, Llc | Varicella-zoster virus immunogen compositions and their uses |
| JP2024543272A (ja) * | 2021-11-29 | 2024-11-20 | ザ ガバニング カウンシル オブ ザ ユニバーシティ オブ トロント | マルチモチーフデンドロン及びその超分子構造ならびにその使用 |
| WO2023126053A1 (en) * | 2021-12-28 | 2023-07-06 | BioNTech SE | Lipid-based formulations for administration of rna |
| CN114349811A (zh) * | 2022-01-05 | 2022-04-15 | 上海交通大学 | 阳离子胆固醇衍生物、纳米复合物及其制备方法和应用 |
| WO2023138666A1 (en) * | 2022-01-19 | 2023-07-27 | Utc Therapeutics (Shanghai) Co., Ltd. | Circular rna and use thereof |
| EP4482819A2 (en) * | 2022-02-24 | 2025-01-01 | Vivasor, Inc. | Novel ionizable cationic lipids |
| US20250188028A1 (en) * | 2022-03-14 | 2025-06-12 | Nanovation Therapeutics Inc. | Synthetic Method for Producing Ionizable Amino Lipids |
| CN118871134A (zh) * | 2022-03-21 | 2024-10-29 | 生物探险有限公司 | 用于增强蛋白质表达的内部核糖体进入位点（IRES）、质粒载体和环状mRNA |
| KR102560772B1 (ko) * | 2022-03-21 | 2023-07-28 | 주식회사 메디치바이오 | 신규한 이온화지질 및 이를 이용한 지질나노입자 조성물 |
| TW202408542A (zh) * | 2022-05-20 | 2024-03-01 | 大陸商浙江健新原力製藥有限公司 | 製備環狀ｒｎａ的方法 |
| US12297285B2 (en) | 2022-06-24 | 2025-05-13 | Orna Therapeutics, Inc. | Circular RNA encoding chimeric antigen receptors targeting BCMA |
| CN119343454A (zh) * | 2022-09-13 | 2025-01-21 | 苏州艾博生物科技有限公司 | 用于合成环状rna的一步法 |
| EP4596605A4 (en) * | 2022-09-30 | 2026-01-14 | Xiamen Sinopeg Biotech Co Ltd | PEGYLATED LIPID CONTAINING A LYSIN NUCLEUS |
| CN117917398A (zh) * | 2022-10-21 | 2024-04-23 | 华中师范大学 | 一种可离子化脂质化合物、核酸药物分子递送系统及应用 |
| CN120390656A (zh) | 2022-11-08 | 2025-07-29 | 欧纳医疗公司 | 环状rna组合物 |
| CN120225500A (zh) * | 2022-11-18 | 2025-06-27 | 韩国生命工学研究院 | 用于活性物质递送的脂质化合物及组合物 |
| AU2023398825A1 (en) | 2022-12-15 | 2025-06-26 | Orna Therapeutics, Inc. | Circular rna compositions and methods |
| CN120390801A (zh) * | 2022-12-20 | 2025-07-29 | 杭州明德生物医药技术有限公司 | 环状rna分离和纯化方法 |
| EP4642434A2 (en) * | 2022-12-29 | 2025-11-05 | Life Technologies Corporation | Lipid compositions on the basis of ionizable lipids, use for delivery to immune cells |
| WO2024151583A2 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations Vii, Llc | Vaccines and related methods |
| WO2024167885A1 (en) | 2023-02-06 | 2024-08-15 | Flagship Pioneering Innovations Vii, Llc | Immunomodulatory compositions and related methods |
| WO2024192420A1 (en) | 2023-03-15 | 2024-09-19 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising polyribonucleotides and uses thereof |
| WO2024192291A1 (en) | 2023-03-15 | 2024-09-19 | Renagade Therapeutics Management Inc. | Delivery of gene editing systems and methods of use thereof |
| EP4680595A2 (en) | 2023-03-15 | 2026-01-21 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| EP4680276A1 (en) | 2023-03-15 | 2026-01-21 | Flagship Pioneering Innovations VI, LLC | Immunogenic compositions and uses thereof |
| KR20240159310A (ko) * | 2023-04-28 | 2024-11-05 | 주식회사 메디치바이오 | 신규한 이온화지질을 이용한 지질나노입자 조성물 |
| EP4698150A1 (en) | 2023-04-19 | 2026-02-25 | Sail Biomedicines, Inc. | Delivery of polynucleotides from lipid nanoparticles comprising rna and ionizable lipids |
| WO2024220752A2 (en) * | 2023-04-19 | 2024-10-24 | Sail Biomedicines, Inc. | Rna therapeutic compositions |
| WO2024233308A2 (en) | 2023-05-05 | 2024-11-14 | Orna Therapeutics, Inc. | Circular rna compositions and methods |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025007148A1 (en) | 2023-06-30 | 2025-01-02 | Orna Therapeutics, Inc. | Polymer lipid nanoparticle compositions for delivering circular polynucleotides |
| WO2025011502A1 (zh) * | 2023-07-07 | 2025-01-16 | 仁景(苏州)生物科技有限公司 | 制备环状rna方法及用于所述方法的核酸序列 |
| WO2025042786A1 (en) | 2023-08-18 | 2025-02-27 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising circular polyribonucleotides and uses thereof |
| WO2025049690A1 (en) | 2023-08-29 | 2025-03-06 | Orna Therapeutics, Inc. | Circular polyethylene glycol lipids |
| AU2024335327A1 (en) | 2023-09-01 | 2026-03-26 | Renagade Therapeutics Management Inc. | Gene editing systems, compositions, and methods for treatment of vexas syndrome |
| WO2025081042A1 (en) | 2023-10-12 | 2025-04-17 | Renagade Therapeutics Management Inc. | Nickase-retron template-based precision editing system and methods of use |
| WO2025085695A1 (en) * | 2023-10-18 | 2025-04-24 | Trustees Of Dartmouth College | Lipid nanoparticle formulations for delivery of nucleic acids to primary human b-cells |
| WO2025101501A1 (en) | 2023-11-07 | 2025-05-15 | Orna Therapeutics, Inc. | Circular rna compositions |
| EP4559898A1 (en) * | 2023-11-24 | 2025-05-28 | AldexChem Kft. | Novel ionizable cationic lipids containing thioether linkage |
| WO2025117969A1 (en) | 2023-12-01 | 2025-06-05 | Orna Therapeutics, Inc. | Process for manufacturing lipid nanoparticles |
| WO2025120230A1 (en) | 2023-12-07 | 2025-06-12 | T-Curx Gmbh | Method of producing leukocytes expressing artificial antigen receptors |
| WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025155753A2 (en) | 2024-01-17 | 2025-07-24 | Renagade Therapeutics Management Inc. | Improved gene editing system, guides, and methods |
| TW202545974A (zh) | 2024-01-26 | 2025-12-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 免疫受體抑制蛋白及相關方法 |
| WO2025174765A1 (en) | 2024-02-12 | 2025-08-21 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025240680A1 (en) | 2024-05-16 | 2025-11-20 | Flagship Pioneering Innovations Vii, Llc | Immunoreceptor inhibitory proteins and related methods |
| WO2025245111A1 (en) | 2024-05-22 | 2025-11-27 | Flagship Pioneering Innovations Vii, Llc | Immunoreceptor targeting proteins and related methods |
| WO2025250751A1 (en) | 2024-05-31 | 2025-12-04 | Orna Therapeutics, Inc. | Circular rna compositions and methods |
| WO2026003582A2 (en) | 2024-06-27 | 2026-01-02 | Axelyf ehf. | Lipids and lipid nanoparticles |
| WO2026006687A1 (en) * | 2024-06-28 | 2026-01-02 | Orbital Therapeutics, Inc. | Circular rna compositions and uses thereof for diseases caused by varicella-zoster virus |
| WO2026006593A1 (en) | 2024-06-28 | 2026-01-02 | Orna Therapeutics, Inc. | Synthetic internal ribosome entry sites |
| WO2026072709A1 (en) | 2024-09-25 | 2026-04-02 | Orna Therapeutics, Inc. | Chimeric antigen receptors targeting bcma |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100305197A1 (en) * | 2009-02-05 | 2010-12-02 | Massachusetts Institute Of Technology | Conditionally Active Ribozymes And Uses Thereof |
| ES2895651T3 (es) * | 2013-12-19 | 2022-02-22 | Novartis Ag | Lípidos y composiciones lipídicas para la administración de agentes activos |
| EP4286012A3 (en) * | 2015-09-17 | 2024-05-29 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| EP3668834B1 (en) * | 2017-08-17 | 2024-10-02 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| CA3100276A1 (en) * | 2018-06-06 | 2019-12-12 | Massachusetts Institute Of Technology | Circular rna for translation in eukaryotic cells |
| US12263248B2 (en) * | 2018-09-19 | 2025-04-01 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| WO2020237227A1 (en) * | 2019-05-22 | 2020-11-26 | Massachusetts Institute Of Technology | Circular rna compositions and methods |
-
2021
- 2021-05-10 AU AU2021269137A patent/AU2021269137A1/en active Pending
- 2021-05-10 US US17/998,219 patent/US20230226096A1/en active Pending
- 2021-05-10 MX MX2022014070A patent/MX2022014070A/es unknown
- 2021-05-10 CN CN202180048567.4A patent/CN116113419A/zh active Pending
- 2021-05-10 CA CA3178111A patent/CA3178111A1/en active Pending
- 2021-05-10 EP EP21727981.9A patent/EP4146285A2/en active Pending
- 2021-05-10 JP JP2022567617A patent/JP2023525270A/ja active Pending
- 2021-05-10 WO PCT/US2021/031629 patent/WO2021226597A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021226597A3 (en) | 2022-03-03 |
| EP4146285A2 (en) | 2023-03-15 |
| CA3178111A1 (en) | 2021-11-11 |
| US20230226096A1 (en) | 2023-07-20 |
| AU2021269137A1 (en) | 2022-12-15 |
| JP2023525270A (ja) | 2023-06-15 |
| CN116113419A (zh) | 2023-05-12 |
| WO2021226597A2 (en) | 2021-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022014070A (es) | Composiciones y metodos de arn circular. | |
| MX2022006854A (es) | Composiciones y metodos de arn circular. | |
| JP7343920B2 (ja) | マトリックス結合ナノベシクルおよびその使用 | |
| AR127142A1 (es) | Arn circular y método de preparación del mismo | |
| CY1125575T1 (el) | Πεγκυλιωμενα λιποσωματα για χορηγηση rna το οποιο κωδικοποιει ενα ανοσογονο | |
| BR112022023554A2 (pt) | Composições e métodos de rna circular | |
| MX2020003995A (es) | Nuevas moleculas de acido nucleico artificiales. | |
| CL2009001001A1 (es) | Anticuerpo anti-factor d del complemento; polinucleotido codificante; vector que comprende dicho polinucleotido; celula huesped que comprende dicho vector; metodo de fabricacion del anticuerpo; composicion farmaceutica que lo comprende; uso del anticuerpo para tratar trastornos inflamatorios o trastornos oculares. | |
| CL2020000501A1 (es) | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos. | |
| CL2020003343A1 (es) | Vectores virales recombinantes con tropismo modificado y usos de los mismos para la introducción dirigida de material genético a células humanas (divisional de la solicitud 201903842) | |
| CY1121122T1 (el) | Πολυαιθυλενογλυκολιωμενα λιποσωματα για απελευθερωση rna που κωδικοποιει ανοσογονο | |
| MX2012000424A (es) | L-asparaginasa pegilada. | |
| CL2022000664A1 (es) | Proteínas de fijación multiespecíficas para tratamiento contra el cáncer | |
| MX2018011384A (es) | Arn de replicacion en trans. | |
| CY1115841T1 (el) | Εμβολια πεπτιδιου παραγομενα απο epha4 | |
| MX358725B (es) | Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden. | |
| MX2022013362A (es) | Composiciones para tratar cancer con mutaciones de kras y usos de las mismas. | |
| CR20220540A (es) | Moléculas de union al antígeno multiespecíficas dirigidas a claudina-6 y sus usos | |
| UY37630A (es) | Combinación farmacéutica, kit, célula huésped que la produce y su uso en métodos para el tratamiento del cáncer | |
| CO2021016301A2 (es) | Arn terapéutico para cáncer de ovario | |
| MX2023007801A (es) | Células t diseñadas. | |
| MX2024015396A (es) | Anticuerpo y su uso | |
| MX2023007229A (es) | Constructo de arn. | |
| Weidensee et al. | Decrypting the Immune Symphony for RNA Vaccines | |
| CL2024003076A1 (es) | Composiciones y métodos para la prevención y el tratamiento de la infección por el virus de la rabia |